Skip to Main Content


Skip Nav Destination

CCR Focus Archive 2013

CCR Focus Archive Home

2017  |  2016  |  2015  |  2014  |  2013  |  2012  |  2011  |  2010  |  2009  |  2008  |  2007  |  2006

Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical Investigation (December 1, 2013)
Novel Agents in Melanoma: A Pipeline for the Future (October 1, 2013)
Progression-Free Survival: Clinical and Statistical Challenges (May 15, 2013)
The Immune System as an Anticancer Agent (March 1, 2013)

2013 CCR Focus Sections

CCR Focus Cover

Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical Investigation
December 1, 2013
Guest Editor: Carlos L. Arteaga, 19 (23) : 6352–6418

On Masterpieces and Breast Cancer Research
Susan E. Bates

Progress in Breast Cancer: Overview
Carlos L. Arteaga

Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer
Aditya Bardia and José Baselga

Incorporating Genomics into Breast Cancer Clinical Trials and Care
Adel Tabchy, Cynthia X. Ma, Ron Bose, and Matthew J. Ellis

Tackling the Diversity of Triple-Negative Breast Cancer
Nicholas C. Turner and Jorge S. Reis-Filh

Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
Xiang H.-F. Zhang, Mario Giuliano, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne

Can Immunity to Breast Cancer Eliminate Residual Micrometastases?
Mary L. Disis and Sasha E. Stanton

AACR Publications Journal-based CME

CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Nancy U. Lin, Laleh Amiri-Kordestani, Diane Palmieri, David J. Liewehr, and Patricia S. Steeg

Back to top

CCR Focus Cover

Novel Agents in Melanoma: A Pipeline for the Future
October 1, 2013
Guest Editors: Keith Flaherty and Patricia LoRusso, 19 (19) : 5282–5328

A Sea Change in Melanoma
Susan E. Bates

The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be
Ryan J. Sullivan, Patricia M. LoRusso, and Keith T. Flaherty

Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy
Mei Li M. Kwong, Bart Neyns, and James C. Yang

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Lawrence N. Kwong and Michael A. Davies

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard and Grant A. McArthur

Back to top

CCR Focus Cover

Progression-Free Survival: Clinical and Statistical Challenges
May 15, 2013
Guest Editor: John J. Crowley, 19 (10) : 2606–2656

PFS: The Endpoint We Love and Love to Hate
Susan E. Bates

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ronald L. Korn and John J. Crowley

Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival
Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Murgo, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Mary W. Redman, Bryan H. Goldman, Michael LeBlanc, Anne Schott, and Laurence H. Baker

Back to top

CCR Focus Cover

The Immune System as an Anticancer Agent
March 1, 2013
Guest Editors: Ignacio Melero and Paolo A. Ascierto, 19 (5) : 995–1062

Waking the Immune System at Last
Susan E. Bates

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Ignacio Melero, Antonio M. Grimaldi, Jose L. Perez-Gracia, and Paolo A. Ascierto

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Paolo A. Ascierto, Michael Kalos, David A. Schaer, Margaret K. Callahan, and Jedd D. Wolchok

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol and Lieping Chen

Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide and Martin J. Glennie

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero, Daniel Hirschhorn-Cymerman, Aizea Morales-Kastresana, Miguel F. Sanmamed, and Jedd D. Wolchok

Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors
Eli Gilboa, James McNamara II, and Fernando Pastor

Close Modal

or Create an Account

Close Modal
Close Modal